Vimta Labs (524394) Q2 26/27 earnings summary

Executive summary

• Q2 FY27 total income rose 9.9% YoY to ₹1,148.87 million; EBITDA grew 10.5% to ₹408 million and PAT rose 3.5% to ₹206.14 million.

• H1 FY27 total income increased 11.8% to ₹2,278 million, with EBITDA up 13.2% to ₹819 million and PAT up 7.3% to ₹416.56 million.

• The Board approved unaudited Q2 and H1 results on October 30, 2026; the statutory auditor issued an unmodified limited review report.

Financial highlights

• Q2 revenue from operations was ₹1,119.83 million versus ₹1,018.48 million; other income was ₹29.04 million.

• Q2 EBITDA margin was 35.5%; PBT was ₹275.25 million versus ₹262.74 million, and basic EPS was ₹4.61 versus ₹4.50.

• H1 revenue from operations was ₹2,210.57 million versus ₹1,994.12 million; PBT rose to ₹558.63 million from ₹515.35 million.

• H1 EBITDA margin was 36%; PAT margin was 18.3%, and basic EPS was ₹9.32 versus ₹8.71.

Outlook and guidance

• Management expects CRADS and clinical research to improve in Q3 and Q4 as active proposals convert; no quarter-specific forecasts were provided.

• Medium-term FY28 targets remain INR 700 crore turnover and a 35%-36% EBITDA margin; the top-line ambition implies 20%-25% CAGR.

• Biologics may take a couple of years to become significant; management targets a 1:1 revenue-to-investment return around year three, potentially year two with faster progress.

• Medium-term EBITDA margin correction of 100-200 bps is expected, mainly from biologics mix; near-term margins are not expected to change significantly.